Correlation Between Ideal Cardiovascular Health Metrics and Plasma hs-CRP Levels in a North China Population: One Four-Year Follow-Up Study

References

• Stevens W, Peneva D, Li JZ, et al. Estimating the future burden of cardiovascular disease and the value of lipid and blood pressure control therapies in China. BMC Health Serv Res. 2016;16(1):175. doi:10.1186/s12913-016-1420-827165638
   PubMed Web of Science ®Google Scholar
• Yang G, Wang Y, Zeng Y, et al. Rapid health transition in China, 1990–2010: findings from the Global Burden of Disease Study 2010. Lancet. 2013;381(9882):1987–2015. doi:10.1016/S0140-6736(13)61097-123746901
   PubMed Web of Science ®Google Scholar
• Yan R, Li W, Yin L, et al. Cardiovascular Diseases and Risk-Factor Burden in Urban and Rural Communities in High-, Middle-, and Low-Income Regions of China: A Large Community-Based Epidemiological Study. J Am Heart Assoc. 2017;6(2). doi:10.1161/JAHA.116.004445.
   Web of Science ®Google Scholar
• Xi B, Liu F, Hao Y, et al. The growing burden of cardiovascular diseases in China. Int J Cardiol. 2014;174(3):736–737. doi:10.1016/j.ijcard.2014.04.09824794557
   PubMed Web of Science ®Google Scholar
• Zhou M, Wang H, Zhu J, et al. Cause-specific mortality for 240 causes in China during 1990–2013: a systematic subnational analysis for the Global Burden of Disease Study 2013. Lancet. 2016;387(10015):251–272. doi:10.1016/S0140-6736(15)00551-626510778
   PubMed Web of Science ®Google Scholar
• Lloyd-Jones DM, Hong Y, Labarthe D, et al. Defining and setting national goals for cardiovascular health promotion and disease reduction: the American Heart Association’s strategic Impact Goal through 2020 and beyond. Circulation. 2010;121(4):586–613. doi:10.1161/CIRCULATIONAHA.109.19270320089546
   PubMed Web of Science ®Google Scholar
• Wu S, Huang Z, Yang X, et al. Prevalence of ideal cardiovascular health and its relationship with the 4-year cardiovascular events in a northern Chinese industrial city. Circ Cardiovasc Qual Outcomes. 2012;5(4):487–493. doi:10.1161/CIRCOUTCOMES.111.96369422787064
   PubMed Web of Science ®Google Scholar
• Zhang Q, Zhou Y, Gao X, et al. Ideal cardiovascular health metrics and the risks of ischemic and intracerebral hemorrhagic stroke. Stroke. 2013;44(9):2451–2456. doi:10.1161/STROKEAHA.113.67883923868276
   PubMed Web of Science ®Google Scholar
• Huet F, Akodad M, Fauconnier J, et al. Anti-inflammatory drugs as promising cardiovascular treatments. Expert Rev Cardiovasc Ther. 2017;15(2):109–125. doi:10.1080/14779072.2017.127377128010154
   PubMed Web of Science ®Google Scholar
• Shayganni E, Bahmani M, Asgary S, et al. Inflammaging and cardiovascular disease: management by medicinal plants. Phytomedicine. 2016;23(11):1119–1126. doi:10.1016/j.phymed.2015.11.00426776956
   PubMed Web of Science ®Google Scholar
• Xue H, Wang J, Hou J, et al. Ideal cardiovascular health behaviors and factors and high sensitivity C-reactive protein: the Kailuan cross-sectional study in Chinese. Clin Chem Lab Med. 2014;52(9):1379–1386. doi:10.1515/cclm-2013-065724791822
   PubMed Web of Science ®Google Scholar
• Tan M, He FJ, Wang C, et al. Twenty-Four-Hour Urinary Sodium and Potassium Excretion in China: A Systematic Review and Meta-Analysis. J Am Heart Assoc. 2019;8(14):e012923. doi:10.1161/JAHA.119.01292331295409
   PubMed Web of Science ®Google Scholar
• Sun L, Zou T, Wang BZ, et al. Epidemiological investigation into the prevalence of abnormal inter-arm blood pressure differences among different ethnicities in Xinjiang, China. PLoS One. 2018;13(1):e0188546. doi:10.1371/journal.pone.018854629346374
   PubMed Web of Science ®Google Scholar
• Wang Z, Gordon-Larsen P, Siega-Riz AM, et al. Sociodemographic disparity in the diet quality transition among Chinese adults from 1991 to 2011. Eur J Clin Nutr. 2017;71(4):486–493. doi:10.1038/ejcn.2016.17927677363
   PubMed Web of Science ®Google Scholar
• Bragg F, Li L, Smith M, et al. Associations of blood glucose and prevalent diabetes with risk of cardiovascular disease in 500 000 adult Chinese: the China Kadoorie Biobank. Diabet Med. 2014;31(5):540–551. doi:10.1111/dme.1239224344928
   PubMed Web of Science ®Google Scholar
• Bergstrom G, Behre CJ, Schmidt C. Moderate intensities of leisure-time physical activity are associated with lower levels of high-sensitivity C-reactive protein in healthy middle-aged men. Angiology. 2012;63(6):412–415. doi:10.1177/000331971142338622072642
   PubMed Web of Science ®Google Scholar
• Abramson JL, Vaccarino V. Relationship between physical activity and inflammation among apparently healthy middle-aged and older US adults. Arch Intern Med. 2002;162(11):1286–1292. doi:10.1001/archinte.162.11.128612038947
   PubMedGoogle Scholar
• Sesso HD, Buring JE, Rifai N, et al. C-reactive protein and the risk of developing hypertension. JAMA. 2003;290(22):2945–2951. doi:10.1001/jama.290.22.294514665655
   PubMed Web of Science ®Google Scholar
• Wang TJ, Gona P, Larson MG, et al. Multiple biomarkers and the risk of incident hypertension. Hypertension. 2007;49(3):432–438. doi:10.1161/01.HYP.0000256956.61872.aa17242302
   PubMed Web of Science ®Google Scholar
• Fogarty AW, Lewis SA, McKeever TM, et al. Is higher sodium intake associated with elevated systemic inflammation? A population-based study. Am J Clin Nutr. 2009;89(6):1901–1904. doi:10.3945/ajcn.2008.2700619386745
   PubMed Web of Science ®Google Scholar
• Wen J, Liang Y, Wang F, et al. Association of C-reactive protein and metabolic syndrome in a rural Chinese population. Clin Biochem. 2009;42(10–11):976–983. doi:10.1016/j.clinbiochem.2009.03.02619358836
   PubMed Web of Science ®Google Scholar
• Dauphinot V, Roche F, Kossovsky MP, et al. C-reactive protein implications in new-onset hypertension in a healthy population initially aged 65 years: the Proof study. J Hypertens. 2009;27(4):736–743. doi:10.1097/HJH.0b013e328326f80119516173
   PubMed Web of Science ®Google Scholar
• Fliser D, Buchholz K, Haller H, et al. Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. Circulation. 2004;110(9):1103–1107. doi:10.1161/01.CIR.0000140265.21608.8E15313950
   PubMed Web of Science ®Google Scholar
• Ridker PM, Danielson E, Rifai N, et al. Valsartan, blood pressure reduction, and C-reactive protein: primary report of the Val-MARC trial. Hypertension. 2006;48(1):73–79. doi:10.1161/01.HYP.0000226046.58883.3216714425
   PubMed Web of Science ®Google Scholar
• Guerrero-Romero F, Simental-Mendia LE, Rodriguez-Moran M. Association of C-reactive protein levels with fasting and postload glucose levels according to glucose tolerance status. Arch Med Res. 2014;45(1):70–75. doi:10.1016/j.arcmed.2013.11.00424326321
   PubMed Web of Science ®Google Scholar
• Rhee EJ, Kim YC, Lee WY, et al. Comparison of insulin resistance and serum high-sensitivity C-reactive protein levels according to the fasting blood glucose subgroups divided by the newly recommended criteria for fasting hyperglycemia in 10059 healthy Koreans. Metabolism. 2006;55(2):183–187. doi:10.1016/j.metabol.2005.08.01016423624
   PubMed Web of Science ®Google Scholar
• Kashima S, Inoue K, Matsumoto M, et al. White blood cell count and c-reactive protein independently predicted incident diabetes: Yuport Medical Checkup Center Study. Endocr Res. 2019;1–11.
   Web of Science ®Google Scholar
• Sung KC, Ryu S, Sung JW, et al. Inflammation in the prediction of type 2 diabetes and hypertension in healthy adults. Arch Med Res. 2017;48(6):535–545. doi:10.1016/j.arcmed.2017.11.01029221802
   PubMed Web of Science ®Google Scholar